News from diamyd medical ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

16 Sep, 2020, 12:04 BST Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about...


14 Sep, 2020, 16:41 BST Phase IIb topline results demonstrate a significant treatment effect of Diamyd® in a previously identified genetic subgroup of individuals with type 1 diabetes

Diamyd Medical today announced the topline results from the placebo-controlled Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd®...


05 Aug, 2020, 08:24 BST Diabetologia publishes results highlighting efficacy of the diabetes vaccine Diamyd® in genetically defined subgroups of type 1 diabetes

Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) has published results from a meta study that demonstrates a...


24 Jun, 2020, 07:56 BST Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020

Developing therapies for type 1 diabetes Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. Further...


04 May, 2020, 12:27 BST Promising Findings From the First Part of a Clinical Trial With Remygen®

The initial safety and dose escalation part of the Phase I/II trial ReGenerate-1 with Remygen® in individuals with long-term type 1 diabetes today...


24 Apr, 2020, 12:02 BST Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®

The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in...


16 Apr, 2020, 18:03 BST Diamyd Medical Opens up for Vaccine Manufacturing in Umeå, Sweden

A new manufacturing facility is being set up in Umeå by Diamyd Medical. The first priority of the new site is to receive the process technology for...


20 Dec, 2019, 16:52 GMT Positive Top-line Results From I/II Trial With Intralymphatic Diamyd®

Diamyd Medical announced today, when all 12 patients have been followed throughout the 30-month period in the open-label trial DIAGNODE-1, that the...


12 Dec, 2019, 20:48 GMT Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials

Diamyd Medical announces that a new analysis based on data from more than 530 individual patients from previous phase III and II trials in Europe and ...


15 Oct, 2019, 11:03 BST Diamyd Medical Enters Agreement for Intralymphatic Diamyd ® Trial in LADA

The agreement with the Norwegian University of Science and Technology in Trondheim (NTNU) refers to a first, investigator initiated clinical Phase II ...


09 Sep, 2019, 14:16 BST Feasibility Study Supports the use of Intralymphatic Injections of Diamyd®

A feasibility study performed as a Master Thesis at Uppsala University and supervised by Diamyd Medical, supports the use of ultrasound guided...


04 Jun, 2019, 07:38 BST New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®

The first seven patients that have now been followed for the entire 30-month period in DIAGNODE-1 continue to show a positive clinical course and are ...


29 May, 2019, 14:12 BST The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1

The approval by the Swedish MPA entails that ReGenerate-1, with Diamyd Medical's GABA-based investigational drug Remygen®, will be expanded from the...


26 Mar, 2019, 07:51 GMT Diamyd Medical Announces Strategic Activities for 2019 and 2020

With experience from clinical trials in more than 1,000 patients with the diabetes vaccine Diamyd®, preparations for a Conditional Marketing...


08 Mar, 2019, 08:13 GMT European Phase IIb Trial in Type 1 Diabetes With the Diabetes Vaccine Diamyd® Close to Being Fully Recruited

91 out of a total of 106 patienter with type 1 diabetes are included in the European phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd®...